Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001-Reference-Cited by-同舟云学术

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Published:2022-06 Issue:6 Volume:17 Page:768-778
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

McCoach Caroline E.,Rolfo Christian,Drilon Alexander,Lacouture Mario,Besse Benjamin,Goto Koichi,Zhu Viola W.,Tan Daniel S.W.,Farajian Stephanie,Potter Laura A.,Kherani Jennifer F.,Soldatenkova Victoria,Olek Elizabeth A.,Muehlenbein Catherine E.,Park Keunchil

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer;Wang;J Clin Oncol,2012

2. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis;Tsuta;Br J Cancer,2014

3. Discovery stories of RET fusions in lung cancer: a mini-review;Takeuchi;Front Physiol,2019

4. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer;Drilon;N Engl J Med,2020

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature;Cancer Treatment Reviews;2024-09

2. Unique hypersensitivity syndrome secondary to selpercatinib;JAAD Case Reports;2024-08

3. Immunological Drug–Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies;Chemical Research in Toxicology;2024-06-24

4. Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer;Journal of Chemotherapy;2024-05-20

5. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis;eBioMedicine;2024-04